Pancreatic Cancer Research

ResearcherUniversitat de GironaActive in the last 2 years

Carmen E. Guerra

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-3891-046X; OpenAlex author ID A5030492647, A5126172776. Sources: OpenAlex.

Their work

Papers
21 (first author 1, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
82
Papers, trials and grants by year

2011: 1 paper · 2012: 2 papers · 2013: 2 papers · 2014: 4 papers · 2015: none · 2016: none · 2017: none · 2018: 1 paper · 2019: none · 2020: none · 2021: none · 2022: 1 paper · 2023: 1 paper · 2024: 1 paper · 2025: 4 papers · 2026: 4 papers

Papers 21

  1. PARP2 deficiency impairs pancreatic cancer progression by promoting genomic instability and antitumor immunity. Co-author DOI 10.1126/sciadv.adu8849↗
  2. Metastatic pancreatic cancer: from human disease to preclinical modelling. Co-author DOI 10.1136/gutjnl-2025-336334↗
  3. U2 snRNP inhibition hampers pancreatic cancer cell viability by disrupting DNA repair proficiency and mitotic checkpoint integrity Co-author DOI 10.1186/s13046-026-03795-3↗
  4. High-fat diet imprints a macrophage-tumor CAMP-P2RX7 axis driving pancreatic cancer initiation, plasticity and metastasis Last author DOI 10.64898/2026.02.10.703309↗
  5. Navigating the complexities of pancreatic ductal adenocarcinoma: A review on therapeutic models and RAS inhibitors. Last author DOI 10.1016/j.addr.2025.115652↗
  6. A targeted combination therapy achieves effective pancreatic cancer regression and prevents tumor resistance. Co-author DOI 10.1073/pnas.2523039122↗
  7. A Phase III Randomized Trial of Integrated Genomics and Avatar Models for Personalized Treatment of Pancreatic Cancer: The AVATAR Trial. Co-author DOI 10.1158/1078-0432.ccr-23-4026↗
  8. Unlocking the Genetic Secrets of Pancreatic Cancer: KRAS Allelic Imbalances in Tumor Evolution. Last author DOI 10.3390/cancers17071226↗
  9. The Peptidoglycan Recognition Protein 1 confers immune evasive properties on pancreatic cancer stem cells. Co-author DOI 10.1136/gutjnl-2023-330995↗
  10. Establishment of Pancreatic Cancer-Derived Tumor Organoids and Fibroblasts From Fresh Tissue. Co-author DOI 10.3791/65229↗
  11. Soluble AXL is a novel blood marker for early detection of pancreatic ductal adenocarcinoma and differential diagnosis from chronic pancreatitis. Co-author DOI 10.1016/j.ebiom.2021.103797↗
  12. Targeting galectin-1 inhibits pancreatic cancer progression by modulating tumor-stroma crosstalk. Co-author DOI 10.1073/pnas.1722434115↗
  13. Parp-1 genetic ablation in Ela-myc mice unveils novel roles for Parp-1 in pancreatic cancer. Co-author DOI 10.1002/path.4384↗
  14. Reply: 'Comments on Stromal disrupting effects of nab-paclitaxel in pancreatic cancer'. Co-author DOI 10.1038/bjc.2014.129↗
  15. Nicotine promotes initiation and progression of KRAS-induced pancreatic cancer via Gata6-dependent dedifferentiation of acinar cells in mice. Co-author DOI 10.1053/j.gastro.2014.08.002↗
  16. Utilizing past and present mouse systems to engineer more relevant pancreatic cancer models. Co-author DOI 10.3389/fphys.2014.00464↗
  17. Genetically engineered mouse models of pancreatic adenocarcinoma. Co-author DOI 10.1016/j.molonc.2013.02.002↗
  18. Stromal disrupting effects of nab-paclitaxel in pancreatic cancer. Co-author DOI 10.1038/bjc.2013.415↗
  19. EGF receptor signaling is essential for k-ras oncogene-driven pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.ccr.2012.08.001↗
  20. What we have learned about pancreatic cancer from mouse models. First author DOI 10.1053/j.gastro.2012.03.002↗
  21. Pancreatitis-induced inflammation contributes to pancreatic cancer by inhibiting oncogene-induced senescence. Co-author DOI 10.1016/j.ccr.2011.05.011↗

Closest collaborators

The 25 strongest of 82 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Vasiliki Liaki · 4 shared papers, 2025–2026 · strength 1.36
  2. Juan Carlos López-Gil · 4 shared papers, 2024–2026 · strength 0.78
  3. Bruno Sáinz · 5 shared papers, 2014–2026 · strength 0.70
  4. Mariano Barbacid · 9 shared papers, 2011–2026 · strength 0.67
  5. Julie Earl · 4 shared papers, 2022–2026 · strength 0.61
  6. Sara Barrambana · 2 shared papers, 2025 · strength 0.55
  7. Neus Martínez‐Bosch · 4 shared papers, 2014–2026 · strength 0.47
  8. Pilar Navarro · 4 shared papers, 2014–2026 · strength 0.47
  9. Ana Galván-del-Rey · 2 shared papers, 2026 · strength 0.46
  10. Alfredo Carrato · 3 shared papers, 2022–2024 · strength 0.40
  11. Peter Y. Yu · 1 shared paper, 2026 · strength 0.39
  12. Jimin Min · 1 shared paper, 2026 · strength 0.39
  13. Anirban Maitra · 1 shared paper, 2026 · strength 0.39
  14. Noemí Manero‐Rupérez · 2 shared papers, 2022–2026 · strength 0.36
  15. Sonia Alcalá · 2 shared papers, 2024–2026 · strength 0.35
  16. Carolina de la Pinta · 2 shared papers, 2023–2024 · strength 0.27
  17. Manuel M. Hidalgo · 3 shared papers, 2013–2025 · strength 0.25
  18. Giuseppe Quero · 1 shared paper, 2026 · strength 0.25
  19. Valentina Panzeri · 1 shared paper, 2026 · strength 0.25
  20. Claudio Sette · 1 shared paper, 2026 · strength 0.25
  21. Veronica Ruta · 1 shared paper, 2026 · strength 0.25
  22. Patricia Sancho · 2 shared papers, 2014–2026 · strength 0.24
  23. Núria Vázquez-Bellón · 1 shared paper, 2026 · strength 0.23
  24. Beatriz Parejo-Alonso · 1 shared paper, 2026 · strength 0.21
  25. Antonio Agostini · 1 shared paper, 2026 · strength 0.21

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.